KRAS and pancreatic intraductal papillary-mucinous neoplasm: The incidence of KRAS or GNAS mutation in patients with IPMN according to the location (head versus body or tail) was compared in eight (Hosoda et al. 2015; Kobayashi et al. 2008; Kondo et al. 1997; Schönleben et al. 2008; Singhi et al. 2014; Uemura et al. 2003; Wada et al. 2004; Wu et al. 2011b) and six (Hosoda et al. 2015; Ideno et al. 2015; Kanda et al. 2013; Singhi et al. 2014; Takano et al. 2014; Wu et al. 2011b) studies, respectively.